MA-HARVEY-PERFORMANCE
15.7.2024 15:00:31 CEST | Business Wire | Press release
Harvey Performance Company (“Harvey Performance” or the “company”), a leading provider of specialized cutting tools for precision machining applications, today announced the acquisition of ATA. Harvey Performance serves the market through industry-leading brands Harvey Tool, Helical Solutions, Micro 100, Titan USA, CoreHog, and Valor Holemaking. ATA is an Ireland-based precision engineering multinational and the parent company of the Karnasch, SGSPRO, ATA Tools, Van Hoorn Carbide, Industrial Tooling Corporation (“ITC”), and Garryson brands.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240715286290/en/
“We couldn’t be more excited about welcoming ATA to the Harvey Performance family,” said Brian Lavelle, Chief Executive Officer of Harvey Performance Company. “This acquisition represents a milestone in the proud history of the company and further establishes our integrated, international business comprised of distinctive brands and product lines.”
Since its inception as a family business in 1963, ATA has remained steadfast in its dedication to manufacturing, supplying, and distributing tools of exceptional quality. Today, it boasts a product offering exceeding 25,000 precision industrial cutting tools which it supplies to leading manufacturing industries, including aerospace, power generation, electronics, and more. ATA –which is headquartered in Ireland and has additional operating locations in the United Kingdom, United States, Germany, The Netherlands, and Switzerland – engineers, manufactures, and distributes its products globally from its seven manufacturing facilities, worldwide.
“We were immediately impressed by ATA, its global team and tremendous collection of brands,” Lavelle said. “Like all Harvey Performance brands, ATA brands have an established reputation for providing outstanding customer service and a dedication to manufacturing the industry’s highest quality products.”
Harvey Performance and ATA are both established leaders in their respective geographies, and the acquisition is expected to create a powerful combination across North America and Europe. The acquisition will bring an outstanding international platform on which Harvey Performance can continue to grow and expand. The ATA management team will continue to drive business for the company outside of the US.
“This acquisition presents great potential for Harvey Performance,” said Harvey Performance Company Senior Vice President of Sales Jerry Gleisner. “It provides Harvey Performance’s North American customers with exposure to some of the best industrial cutting tools that Europe has to offer.”
Peter Cosgrove, CEO of ATA, said, "ATA is delighted to join Harvey Performance Company, with whom we share a unified global vision for the future. We’re focused on expanding Harvey Performance's brands across Europe and beyond while introducing ATA's leading brands to Harvey Performance’s customers. I am honoured to join the Harvey Performance board. Our management team is looking forward to collaborating with our new colleagues, and our primary focus remains on driving business growth globally.”
“We are excited for the many growth opportunities enabled by the combination of Harvey Performance and ATA’s highly complementary offerings and talented leadership teams,” said Ted Rainaud, Managing Director, Berkshire Partners. “This acquisition represents a significant expansion of Harvey Performance’s product offering and geographic presence. We look forward to supporting the continued growth and expansion of the combined business.”
ATA’s investment partners Development Capital and the Ireland Strategic Investment Fund, who invested in 2017 and 2019 respectively, will exit as a result of the transaction.
Andrew Bourg, Co-founder and Director of Development Capital said, “We are delighted to see ATA attract a company the caliber of Harvey Performance, reflecting the success of the vision for the sector by the ATA management team. During the investment period we have been delighted to help ATA scale significantly and develop into an international leader in the cutting tools industry.”
Brian O’Connor, Ireland Strategic Investment Fund said, “ISIF’s investment in ATA is a clear example of its double bottom line mandate in action, investing on a commercial basis to support the scaling of an Irish indigenous business globally, and so supporting economic activity and the creation of high value employment in Ireland. Today’s announcement reflects a strong performance by the ATA team, a positive outcome for the company and a strong investment return for ISIF.”
Piper Sandler acted as exclusive financial advisor to Harvey Performance Company and Berkshire Partners on the acquisition of ATA. Houlihan Lokey acted as exclusive financial advisor to ATA.
About Harvey Performance Company
Harvey Performance Company strives to offer unique and innovative products to solve the industries’ most challenging machining requirements. Its distinct brands, Harvey Tool, Helical Solutions, Micro 100, Titan USA, CoreHog, and Valor Holemaking serve specialty needs and markets with a shared commitment to delivering high quality products and superior service. The brands offer a broad range of products and services that help support machinists, engineers, and CNC programmers while giving their shops a competitive advantage. Harvey Performance Company has a proud history of doing business the right way – offering fast, friendly service; providing comprehensive product support; and treating customers, suppliers, and shareholders in a way that builds strategic, strong, and enduring relationships. For more information, visit www.harveyperformance.com.
About ATA
ATA is an Irish headquartered manufacturer and supplier of precision cutting tools for industrial leaders around the globe. ATA serves over 7,500 customers in 90 countries. ATA was acquired in 2008 by Peter Cosgrove (CEO) and equity investors. Today the business has operating facilities located across Ireland, Germany, Switzerland, the UK, the Netherlands, and the US, and employs close to 500 people. Its leading brands Karnasch, SGSPRO, ATA Tools, Van Hoorn Carbide, and ITC and Garryson, are recognized as industry leaders throughout Europe. For more information, visit www.atagroup.com.
About Berkshire Partners
Berkshire Partners is a 100% employee-owned, multi-sector specialist investor in private and public equity. The firm’s private equity team invests in well-positioned, growing companies across services & industrials, technology & communications, consumer, and healthcare. Since inception, Berkshire Partners has made more than 150 private equity investments and has a strong history of collaborating with management teams to grow the companies in which it invests. The firm's public equity group, Stockbridge, founded in 2007, manages a concentrated portfolio seeking attractive long-term investments. The firm’s Stockbridge and Private Equity teams frequently collaborate and leverage their collective industry expertise across sectors. For additional information, visit www.berkshirepartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240715286290/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom